Headquartered in North Chicago, IL Fiscal year ends December NYSE: ABBV abbvie.com
AbbVie is a global biopharmaceutical company focused on discovering and delivering innovative medicines across several key therapeutic areas, including immunology, neuroscience, and oncology, as well as aesthetics products and services through its Allergan Aesthetics portfolio. Its immunology franchise is anchored by Skyrizi (risankizumab) and Rinvoq (upadacitinib), which have become major growth drivers as the legacy Humira (adalimumab) franchise faces biosimilar competition. In neuroscience, the company markets Vraylar (cariprazine) for psychiatric disorders, Botox Therapeutic for neurological conditions, and migraine treatments Ubrelvy and Qulipta, along with Vyalev for Parkinson's disease. The oncology portfolio includes Venclexta (venetoclax) for hematologic malignancies, Imbruvica (ibrutinib) for blood cancers, Elahere for ovarian cancer, and the bispecific antibody Epkinly (epcoritamab) co-developed with Genmab for lymphoma. The aesthetics business encompasses Botox Cosmetic, the Juvederm Collection of dermal fillers, and the newly approved rapid-onset neurotoxin Boey. AbbVie is actively expanding its pipeline through acquisitions, including the pending acquisition of Apogee Therapeutics to deepen its immunology portfolio with novel IL-13 and TSLP-targeting therapies for atopic dermatitis and asthma. Updated
A physician-scientist joining the board of a $504.7 billion drugmaker signals where AbbVie wants its oversight depth as Skyrizi and Rinvoq face fresh immunology competition. His Form 3 opens a filing trail worth tracking for future buys.
AbbVie set a new 52-week high at $289.08, topping its October 16 peak by 1.28% and marking the fourth record in a month. The $511 billion drugmaker has climbed out of an April trough near $199.
A 5.5% raise to $1.73 a quarter says management sees cash flow holding up even as Humira fades. Buy after Thursday and you miss this payout; the indicated yield sits at 2.44%.
A 3.1% intraday jump to $284.58 is an outsized day for a $503 billion defensive pharma name, landing a day after new Phase 3 AFFIRM data on subcutaneous SKYRIZI in Crohn's disease. Immunology is the growth engine investors are repricing.
A 3.1% slide to $273.85 lands minutes after new Phase 3 AFFIRM data for subcutaneous Skyrizi in Crohn's disease hit the wire. Skyrizi is the growth engine meant to carry the post-Humira era, so the market's read on this data matters.
AbbVie set a fresh 52-week high at $272.42, the second straight day of records for the drugmaker. Keep an eye on whether it holds.
AbbVie cleared its August record with a fresh 52-week high at $266.28, 0.12% above the prior peak, on the same day it announced FDA approval of JUVMO. A $470.9 billion pharma making new highs is a momentum signal income investors rarely get.
Sessions dumped a big pharma name and Alphabet on the same day, then filed within four days, an unusually fast turnaround that pins down the timing. Paired healthcare and megacap tech selling from a sitting House member is a signal to catch before the next leg of either trade.
When a drugmaker's top product loses patent protection, the dividend usually takes the hit. Four pharma giants are each betting on newer drugs to fill the gap, but how close each one…
Treasury yields have turned dividend investing into a minefield, but five mega-caps have quietly raised their payouts through every rate spike, recession, and patent cliff of the past four decades. The question…
Johnson and Johnson just posted a quarter where one business charged ahead while another quietly stalled, and which side wins out will determine whether the stock earns its premium valuation over rivals…
Three popular dividend stocks are paying out well above their free cash flow, and the gap between what each one earns and what it sends to shareholders reveals very different risks hiding…
Social Security raises are locked to a government formula, but a growing number of retirees are routing their income strategy around it entirely, and the stocks they are buying span five very…
Two option-income ETFs sell calls against the same index, pay nearly identical yields, and yet one nearly doubled the other's total return over the past year. The way each fund is built…
Johnson & Johnson just posted a quarter that sent shares sliding despite a headline beat, yet analysts keep piling into the bull camp with price targets well above current levels. Here is…
AbbVie's stock has surged nearly 29% this year, but a rising share price compresses the yield even as the dividend keeps growing. Before adding shares for income, consider what the pending Apogee…
Both are Dividend Kings with decades of consecutive raises, but Medtronic and Abbott reward income investors in fundamentally different ways, and choosing the wrong one in retirement could cost you more than…
Every big pharma company eventually watches its best-selling drug go generic, yet some keep raising their dividends anyway. The five names on this list have already replaced their fading blockbusters with something…
Two of these five dividend stocks just took a beating in October, and that selloff quietly pushed their yields to levels that make the safer-looking names on the list look stingy by…
Eli Lilly trades at a premium multiple, yet its revenue growth dwarfs every major pharma peer by a wide margin. Whether that gap justifies buying shares near all-time highs depends on one…
Skyrizi and Rinvoq are growing fast, a blockbuster acquisition just closed, and the FDA handed AbbVie a fresh approval, yet the stock sits just shy of a price target that has Wall…
A 5% Treasury yield raises the bar for every dividend stock in a retirement portfolio, and not every high-yielder clears it. These five names span telecom, real estate, consumer staples, utilities, and…
Three of these six income stocks beat current Treasury bill yields, but a higher number on the label does not settle the argument once taxes, reinvestment risk, and dividend safety enter the…
AbbVie is a global biopharmaceutical company focused on discovering and delivering innovative medicines across several key therapeutic areas, including immunology, neuroscience, and oncology, as well as aesthetics products and services through its Allergan Aesthetics portfolio.
24/7 Wall St.'s 12-month price target for ABBV is $289.88, rated Hold. The Wall Street consensus target is $284.79. ABBV price prediction →
